Exclusive: Victims’ commissioner makes formal complaint after committee session left one attender ‘shocked, upset and extremely distressed’ Victims of rape and sexual violence have told parliamentarians they felt anxious and distressed during a Westminster evidence session, with one stating that witnessing “pugnacious” questioning had resulted in her “breaking down, sobbing and struggling to breat...
Exclusive: Victims’ commissioner makes formal complaint after committee session left one attender ‘shocked, upset and extremely distressed’ Victims of rape and sexual violence have told parliamentarians they felt anxious and distressed during a Westminster evidence session, with one stating that witnessing “pugnacious” questioning had resulted in her “breaking down, sobbing and struggling to breathe”. The victims’ commissioner has made a formal complaint to the chair of an influential group of MPs after a highly charged evidence session carried out by the public bill committee for the courts and tribunals bill about controversial changes to jury trials. Continue reading...
William Jacob Savage, Chief Medical Officer of Disc Medicine (NASDAQ:IRON) , reported the sale of 5,731 shares of common stock in multiple open-market transactions on April 13, 2026, according to an SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average purchase price ($66.38). Note: 1-year performance is calculated using April 13, 2026 as the reference date. Continue reading
William Jacob Savage, Chief Medical Officer of Disc Medicine (NASDAQ:IRON) , reported the sale of 5,731 shares of common stock in multiple open-market transactions on April 13, 2026, according to an SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average purchase price ($66.38). Note: 1-year performance is calculated using April 13, 2026 as the reference date. Continue reading
Earnings Call Insights: RTX Corporation (RTX) Q1 2026 Management View "We delivered very strong performance to start the year" (Chairman & CEO Christopher Calio). RTX reported "adjusted sales were $22.1 billion" and "adjusted EPS of $1.78," alongside "free cash flow of $1.3 billion" (Chairman & CEO Calio). "Our book-to-bill in the quarter was 1.14, and our backlog is a record $271 billion" (Chairm...
Earnings Call Insights: RTX Corporation (RTX) Q1 2026 Management View "We delivered very strong performance to start the year" (Chairman & CEO Christopher Calio). RTX reported "adjusted sales were $22.1 billion" and "adjusted EPS of $1.78," alongside "free cash flow of $1.3 billion" (Chairman & CEO Calio). "Our book-to-bill in the quarter was 1.14, and our backlog is a record $271 billion" (Chairman & CEO Calio). Calio highlighted defense awards including "over $3 billion for F135 lot 19 production" at Pratt, Collins awards "close to $3 billion," and Raytheon awards of "$6.6 billion" including Patriot and LTAMDS-related wins (Chairman & CEO Calio). "As we previously announced, Raytheon signed 5 landmark framework agreements" for critical munitions, and "once finalized, these agreements would provide firm demand signals" over "the next decade" (Chairman & CEO Calio). He said RTX has already "invested nearly $900 million in CapEx over the last 3 years" at key sites and expects to make "significant additional investments going forward" (Chairman & CEO Calio). "We are updating our full year outlook" (Executive VP & CFO Neil Mitchill). Mitchill said RTX is raising adjusted sales outlook to "$92.5 billion to $93.5 billion" and adjusted EPS to "$6.70" to "$6.90," while keeping free cash flow outlook at "$8.25 billion" to "$8.75 billion" (Executive VP & CFO Mitchill). Outlook "We’re raising our full year outlook for adjusted sales and EPS and maintaining our free cash flow outlook" (Chairman & CEO Calio). Management attributed the raise to "continued defense strength" and "the performance we saw at Raytheon" (Executive VP & CFO Mitchill). Mitchill raised expected defense sales growth to "mid- to high single digits" from "mid-single digits," while keeping commercial expectations: "commercial OE sales to grow mid-single digits" and "commercial aftermarket sales to grow high single digits" (Executive VP & CFO Mitchill). Versus the prior quarter’s initial 2026 guide of $92B-$93...
Key PointsThe CEO of IMAX sold 120,132 common shares for $4.46 million across three open-market transactions on April 13, April 14, and April 15, 2026.
Key PointsThe CEO of IMAX sold 120,132 common shares for $4.46 million across three open-market transactions on April 13, April 14, and April 15, 2026.
Here are the key takeaways from Kevin Warsh ’s remarks at his confirmation hearing to be the next chairman of the Federal Reserve . He testified before the US Senate Banking Committee on Tuesday. Warsh repeatedly pledged to act independently if he’s confirmed as the next Fed chair, rejecting Democrats’ concerns he would be a “sock puppet” for the president He called for a slew of changes to the wa...
Here are the key takeaways from Kevin Warsh ’s remarks at his confirmation hearing to be the next chairman of the Federal Reserve . He testified before the US Senate Banking Committee on Tuesday. Warsh repeatedly pledged to act independently if he’s confirmed as the next Fed chair, rejecting Democrats’ concerns he would be a “sock puppet” for the president He called for a slew of changes to the way the US central bank makes its decisions, including a new framework for dealing with inflation and a new way of communicating with the public Warsh said Trump never asked him to commit to any particular rate decision Warsh committed to selling his financial assets in line with an agreement with the Office of Government Ethics Markets continued to be driven by news on Iran: Oil prices rose, stocks were lower and Treasury yields rose alongside the dollar To access the full live blog, click here to read on the Terminal and here online.
Earnings Call Insights: Northrop Grumman (NOC) Q1 2026 Management View “First quarter organic sales were up 5%, a great start to the year and consistent with our full year expectations,” said (Chair, CEO & President Kathy Warden), while emphasizing agreements reached with customers “to accelerate the Sentinel program, increase the rate at which we build the B-21, become a second source supplier of...
Earnings Call Insights: Northrop Grumman (NOC) Q1 2026 Management View “First quarter organic sales were up 5%, a great start to the year and consistent with our full year expectations,” said (Chair, CEO & President Kathy Warden), while emphasizing agreements reached with customers “to accelerate the Sentinel program, increase the rate at which we build the B-21, become a second source supplier of solid rocket motors on several programs and ramp our rate of production on another handful of programs.” Warden tied near-term demand to production scale investments: “in the last 2 years, we've opened over 20 new facilities and added more than 2 million square feet of manufacturing space across the United States,” and said the company invested “more than $2 billion over the past several years” in solid rocket motors and munitions capacity; she added, “Our tactical SRM production capacity has already doubled, and we have further expansion, which will be completed by 2027.” On flagship programs, Warden said Sentinel acceleration plans include “Milestone B decision later this year, first flight in 2027 and initial operating capability in the early 2030s,” and said B-21 received the “Lot 4 LRIP award” in Q1 and has an agreement “to increase the annual production rate of the B-21 by 25%.” She also flagged missile defense momentum: “Shortly after the close of the quarter, we secured an award to accelerate development of the Glide Phase Interceptor, bringing the total contract value to $1.3 billion.” “Awards totaled $9.8 billion in Q1, and we ended the period with $96 billion in backlog,” said (Corporate VP & CFO John Greene), adding: “First quarter sales were $9.9 billion, up 4% year-over-year,” and “First quarter diluted EPS was $6.14.” Outlook Greene said, “We are reaffirming our outlook for sales, earnings and cash,” and kept full-year 2026 sales at “between $43.5 billion and $44 billion,” while also guiding near-term cadence: “For the second quarter, we expect high single-d...
alexsl Morgan Stanley upgraded Arrowhead Pharmaceuticals ( ARWR ) to Overweight from Equal Weight and raised its price target to $100 from $78, citing major catalysts expected from the California-based biotech over the next 12 months. Analyst Michael Ulz argued that data anticipated in Q3 2026 from the company’s Phase 3 SHASTA trials for its lead asset plozasiran in severe hypertriglyceridemia (SH...
alexsl Morgan Stanley upgraded Arrowhead Pharmaceuticals ( ARWR ) to Overweight from Equal Weight and raised its price target to $100 from $78, citing major catalysts expected from the California-based biotech over the next 12 months. Analyst Michael Ulz argued that data anticipated in Q3 2026 from the company’s Phase 3 SHASTA trials for its lead asset plozasiran in severe hypertriglyceridemia (SHTG) is “an important catalyst” for Arrowhead ( ARWR ). Ulz expects positive data from SHASTA 3 and 4 trials and the treatment to generate $3.2B in adjusted peak sales in SHTG compared to $1.7B in his prior forecast. “While enthusiasm around SHTG has already driven notable share appreciation, we see opportunity for further upside supported by our higher sales expectations,” the analyst wrote. Over the next 12 months, Ulx cites additional catalysts, including initial results for ARWR’s Alzheimer’s candidate ARO-MAPT in healthy volunteers and initial Phase 1/2 data for its hyperlipidemia candidate ARO-DIMER-PA expected in Q3 2026 and H2 2026, respectively. More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline Seeking Alpha’s Quant Rating on Arrowhead Pharmaceuticals
Jamie Dimon ’s letter to JPMorgan Chase & Co. shareholders published this month runs to about 25,000 words. For Wall Street, two in particular stand out: “ Citadel Securities .” The rare callout of the market maker by the CEO of America’s biggest bank in his annual missive — in a section on the lender’s fierce competition — comes as Citadel Securities makes a bold new push into territory dominated...
Jamie Dimon ’s letter to JPMorgan Chase & Co. shareholders published this month runs to about 25,000 words. For Wall Street, two in particular stand out: “ Citadel Securities .” The rare callout of the market maker by the CEO of America’s biggest bank in his annual missive — in a section on the lender’s fierce competition — comes as Citadel Securities makes a bold new push into territory dominated by JPMorgan and its peers: Handling equity block trades for the likes of hedge funds, asset managers, and pensions. It’s the opposite of the small-size, high-volume stock business on which Ken Griffin ’s firm built its name. The effort offers the potential for healthy fees and an even wider view into all corners of equity trading, but also raises the prospect of heightened tensions with the biggest incumbents like JPMorgan — who are often Citadel Securities’ lenders and even clients. “Being a bank is not at all a goal, not even remotely,” Jim Esposito , president of Citadel Securities, said in an interview from the firm’s headquarters in Miami. “We’re focused on solving our clients’ biggest challenges, which will allow us to continue to grow.” Despite such assurances, rivalry between the firms in certain areas is inevitable. With the two now directly competing, JPMorgan stopped sending pieces of its own big equity orders to Citadel Securities, according to people familiar with the matter, who asked not to be identified discussing private matters. The high-speed trader has also been raiding banks for talent to help grow its business — including at least one key hire from Dimon’s team. A spokesperson for JPMorgan declined to comment. To succeed in its new endeavor, Citadel Securities will have to manage a culture shift as those bankers join an organization built by mathematicians and engineers. Plus it has to take on the likes of JPMorgan without the suite of additional services offered by the biggest banks. Yet with their advanced technology and willingness to commit capita...
ASM International NV projected revenue for the second quarter that exceeded analysts’ estimates, underscoring that artificial intelligence investments are driving demand for the Dutch chip-equipment maker’s gear. Revenue will be about €980 million ($1.2 billion) for the three months through June, at constant currency, with a range of 5% above or below that level, the Almere, Netherlands-based firm...
ASM International NV projected revenue for the second quarter that exceeded analysts’ estimates, underscoring that artificial intelligence investments are driving demand for the Dutch chip-equipment maker’s gear. Revenue will be about €980 million ($1.2 billion) for the three months through June, at constant currency, with a range of 5% above or below that level, the Almere, Netherlands-based firm said in a statement after market hours on Tuesday. That compares with the average analyst estimate of €886.8 million, according to data compiled by Bloomberg. ASM shares rose as much as 9.5% to €856.20 apiece on Wednesday morning in Amsterdam, the highest on record. “With AI adoption broadening and workloads for new use cases scaling up rapidly, compute capacity is increasingly becoming the main constraint, driving accelerated investment in AI infrastructure,” Chief Executive Officer Hichem M’Saad said in the statement. That is “increasing both customer investments and the urgency for tool deliveries,” he said. As listed firms from Alphabet Inc. to startups such as OpenAI earmark billions for the build-out of data centers and related infrastructure this year alone, chip-equipment firms are also reaping the benefits. ASM has seen the soaring appetite for high-performance chips, which are needed to power data centers, trickle down in terms of demand for its technologies . Christophe Fouquet , the CEO of Dutch lithography tool maker ASML Holding NV , said this month that demand for chips is “ outpacing supply ,” prompting chipmakers to accelerate their plans to add capacity. The company raised its full-year sales outlook on the back of the AI boom. Read More: Big Tech to Spend $650 Billion This Year as AI Race Intensifies ASM makes what are known as deposition tools, which are used to build advanced chips. It has seen strong momentum from customers transitioning to the 2-nanometer technology node for so-called gate-all-around chip architecture, where its machines can deposit ...
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. 1. The stock market turned lower after Tuesday's Morning Meeting ended. A possible culprit: a rise in oil prices ahead of the Iran war ceasefire agreement set to end Wednesday. After holding steady in morning trade, U.S. oil benchmark West Texas Inte...
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. 1. The stock market turned lower after Tuesday's Morning Meeting ended. A possible culprit: a rise in oil prices ahead of the Iran war ceasefire agreement set to end Wednesday. After holding steady in morning trade, U.S. oil benchmark West Texas Intermediate crude rose about 4% to $93 per barrel. Before the opening bell, President Donald Trump told CNBC he thinks the U.S. will "end up with a great deal" with Iran to end the war. Even before stocks rolled over, Jim Cramer said the market was having a "whacky day," as he pointed to notable moves across a variety of corners such as banks, defense stocks, semiconductors and software. Meanwhile, the Club initiated a new position in Arm Holdings on Monday. Shares of Arm were fractionally higher Tuesday. 2. CrowdStrike was upgraded to a buy-equivalent rating from hold by KeyBanc, which also issued a $525 price target. Analysts said AI tailwinds have arrived, arguing that Anthropic's Mythos model is a catalyst to AI-driven cybersecurity demand. "That upgrade was against the grain," Jim said, because many people think Anthropic is trying to replace companies like CrowdStrike. On the contrary, Jim said he's discussed with CrowdStrike CEO George Kurtz about how the company "is the great hope and will have more customers than ever" in a world filled with AI-enabled cyberattacks. "This stock is well off its high. And it's crazy," Jim said. Analysts, however, held off on upgrading our other cyber name, Palo Alto Networks , saying they want to see clearer execution on recent deals to buy CyberArk and Chronosphere before turning more bullish. 3. Capital One reports Tuesday night after the closing bell. The company reported a disappointing quarter the last time around, with higher investments resulting in an earnings-per-share miss. Jim said he's a little wary about the stock rallying ...